A Glucocorticoid-Fas axis controls immune evasion during metastatic seeding [CUT&Run_4T1-Dex]

Metastasis is the major cause of death for patients with Triple Negative Breast Cancer (TNBC) and other solid malignancies. Metastases arise from cancer cells that disseminate from the original tumour, survive systemic immune surveillance, and colonize new organs. Little is known about how initial disseminated tumour cells (DTCs) overcome anti-tumour immunity upon seeding a new organ. Here we used a visible antigen in a model of TNBC with cognate CD8+ T cells to interrogate mechanisms of immune evasion in early metastatic seeding. Analysis of surviving DTCs revealed Glucocorticoid Receptor (GR) activation as a key driver of resistance to both CD8+ T cells and Natural Killer (NK) cells. Niche profiling using an optimized labelling tool uncovered Fas-FasL as a key pan-cytotoxic pathway against DTCs, which is repressed by GR activation. Pharmacologic inhibition of GR in combination with immunotherapy reduced metastatic burden and expanded lifespan in mice. Thus, we discovered a novel mechanism of immune evasion that operates specifically in DTCs, illustrating the unique immune-cancer interactions at this stage in the metastatic cascade. Our findings suggest that there are therapeutic opportunities to eliminate DTCs, separately from treatments aimed at primary tumours, with GR inhibition as one promising target. Overall design: 4T1 breast tumour cells were treated with Dexamethasone or vehicle control for one week in vitro. Tumour cells were collected and ChIP was performed using a Glucocorticoid Receptor (GR) antibody. CUT&Run was performed on the resulting DNA. Details are included under Fig. 4.